Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients

Phase 4

Terminated

Conditions: Pharyngotonsillitis

Interventions: Drug: Ketoprofen
Drug: Placebo (for Ketoprofen)
Drug: Amoxicillin

First Posted Date: 2008-12-01

Last Posted Date: 2014-10-24

Lead Sponsor: Sanofi

Target Recruit Count: 106

Registration Number: NCT00799838

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

Phase 2

Completed

Conditions: Severe Peripheral Artery Occlusive Disease

First Posted Date: 2008-11-25

Last Posted Date: 2017-06-08

Lead Sponsor: Sanofi

Target Recruit Count: 71

Registration Number: NCT00798005

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Immunogenicity and Safety of Adacel Polio Vaccine

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Pertussis
Poliomyelitis

Interventions: Biological: TdcP-IPV vaccine

First Posted Date: 2008-11-25

Last Posted Date: 2012-11-26

Lead Sponsor: Sanofi

Target Recruit Count: 132

Registration Number: NCT00797511

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Non-Hodgkin

First Posted Date: 2008-11-24

Last Posted Date: 2012-07-17

Lead Sponsor: Sanofi

Target Recruit Count: 77

Registration Number: NCT00796731

Locations: 🇫🇷
Sanofi-Aventis Investigational Site Number 250005, Rennes, France
🇫🇷
Sanofi-Aventis Investigational Site Number 250004, Creteil Cedex, France
🇫🇷
Sanofi-Aventis Investigational Site Number 250003, Rouen Cedex, France

and more 3 locations